Clinical Characteristics and Prognostic Factors of Primary Bone Diffuse Large B-Cell Lymphoma: A Retrospective Study. (PubMed, Cancer Med) - Sep 18, 2026 - "PB-DLBCL often presents with advanced disease but demonstrates generally favorable survival in the rituximab era. Baseline IPI remains a robust predictor of OS, while hypoalbuminemia independently predicts disease progression."
Biomarker • Journal • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|
|
Junning Cao; Kebing Chen; Qunling Zhang; Shengjian Zhang; Xuejun Ma; Yizhen Liu; Yuling Lu; Zhenbo Hou
|